{"title":"非创伤性脑出血患者法莫替丁给药途径的生存率分析：基于 MIMIC-IV 数据库。","authors":"Ling Chen, Yan Wang","doi":"10.1080/14737167.2024.2394113","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study compared the survival outcomes of non-traumatic intracerebral hemorrhage (ICH) patients with different famotidine administration routes and explored related risk factors.</p><p><strong>Methods: </strong>Data from ICH patients between 2008-2019 were extracted from the MIMIC-IV database. Survival differences between patients with intravenous (IV) and non-intravenous (Non-IV) famotidine administration were analyzed using Cox analysis and Kaplan-Meier survival curves.</p><p><strong>Results: </strong>The study included 351 patients, with 109 in the IV group and 84 in the Non-IV group after PSM. Cox analysis revealed that survival was significantly associated with age (HR = 1.031, 95%CI:1.011-1.050, <i>p</i> = 0.002), chloride ions (HR = 1.061, 95%CI:1.027-1.096, <i>p</i> < 0.001), BUN (HR = 1.034, 95%CI:1.007-1.062, <i>p</i> = 0.012), ICP (HR = 1.059, 95%CI:1.027-1.092, <i>p</i> < 0.001), RDW (HR = 1.156, 95%CI:1.030-1.299, <i>p</i> = 0.014), mechanical ventilation (HR = 2.526, 95%CI:1.341-4.760, <i>p</i> = 0.004), antibiotic use (HR = 0.331, 95%CI:0.144-0.759, <i>p</i> = 0.009), and Non-IV route (HR = 0.518, 95%CI:0.283-0.948, <i>p</i> = 0.033). Kaplan-Meier curves showed a significantly higher 30-day survival rate in the Non-IV group (<i>p</i> = 0.011), particularly in patients with normal ICP (HR = 0.518, 95%CI:0.283-0.948, <i>p</i> = 0.033).</p><p><strong>Conclusion: </strong>Non-IV famotidine administration significantly improves 30-day survival of ICH patients, especially for those with normal ICP, compared to IV administration.</p>","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Survival analysis of famotidine administration routes in non-traumatic intracerebral hemorrhage patients: based on the MIMIC-IV database.\",\"authors\":\"Ling Chen, Yan Wang\",\"doi\":\"10.1080/14737167.2024.2394113\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study compared the survival outcomes of non-traumatic intracerebral hemorrhage (ICH) patients with different famotidine administration routes and explored related risk factors.</p><p><strong>Methods: </strong>Data from ICH patients between 2008-2019 were extracted from the MIMIC-IV database. Survival differences between patients with intravenous (IV) and non-intravenous (Non-IV) famotidine administration were analyzed using Cox analysis and Kaplan-Meier survival curves.</p><p><strong>Results: </strong>The study included 351 patients, with 109 in the IV group and 84 in the Non-IV group after PSM. Cox analysis revealed that survival was significantly associated with age (HR = 1.031, 95%CI:1.011-1.050, <i>p</i> = 0.002), chloride ions (HR = 1.061, 95%CI:1.027-1.096, <i>p</i> < 0.001), BUN (HR = 1.034, 95%CI:1.007-1.062, <i>p</i> = 0.012), ICP (HR = 1.059, 95%CI:1.027-1.092, <i>p</i> < 0.001), RDW (HR = 1.156, 95%CI:1.030-1.299, <i>p</i> = 0.014), mechanical ventilation (HR = 2.526, 95%CI:1.341-4.760, <i>p</i> = 0.004), antibiotic use (HR = 0.331, 95%CI:0.144-0.759, <i>p</i> = 0.009), and Non-IV route (HR = 0.518, 95%CI:0.283-0.948, <i>p</i> = 0.033). Kaplan-Meier curves showed a significantly higher 30-day survival rate in the Non-IV group (<i>p</i> = 0.011), particularly in patients with normal ICP (HR = 0.518, 95%CI:0.283-0.948, <i>p</i> = 0.033).</p><p><strong>Conclusion: </strong>Non-IV famotidine administration significantly improves 30-day survival of ICH patients, especially for those with normal ICP, compared to IV administration.</p>\",\"PeriodicalId\":12244,\"journal\":{\"name\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Pharmacoeconomics & Outcomes Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737167.2024.2394113\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2024.2394113","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
Survival analysis of famotidine administration routes in non-traumatic intracerebral hemorrhage patients: based on the MIMIC-IV database.
Objective: This study compared the survival outcomes of non-traumatic intracerebral hemorrhage (ICH) patients with different famotidine administration routes and explored related risk factors.
Methods: Data from ICH patients between 2008-2019 were extracted from the MIMIC-IV database. Survival differences between patients with intravenous (IV) and non-intravenous (Non-IV) famotidine administration were analyzed using Cox analysis and Kaplan-Meier survival curves.
Results: The study included 351 patients, with 109 in the IV group and 84 in the Non-IV group after PSM. Cox analysis revealed that survival was significantly associated with age (HR = 1.031, 95%CI:1.011-1.050, p = 0.002), chloride ions (HR = 1.061, 95%CI:1.027-1.096, p < 0.001), BUN (HR = 1.034, 95%CI:1.007-1.062, p = 0.012), ICP (HR = 1.059, 95%CI:1.027-1.092, p < 0.001), RDW (HR = 1.156, 95%CI:1.030-1.299, p = 0.014), mechanical ventilation (HR = 2.526, 95%CI:1.341-4.760, p = 0.004), antibiotic use (HR = 0.331, 95%CI:0.144-0.759, p = 0.009), and Non-IV route (HR = 0.518, 95%CI:0.283-0.948, p = 0.033). Kaplan-Meier curves showed a significantly higher 30-day survival rate in the Non-IV group (p = 0.011), particularly in patients with normal ICP (HR = 0.518, 95%CI:0.283-0.948, p = 0.033).
Conclusion: Non-IV famotidine administration significantly improves 30-day survival of ICH patients, especially for those with normal ICP, compared to IV administration.
期刊介绍：
Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review.
The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections:
Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
